Experience of oncopaz cooperative group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast

Oncology (Switzerland)

Volumn 54, Issue 1, 1997, Pages 30-37

  Feliu, Jaime ^a   BarÓn, M Gonzàlez ^a   Zamora, P ^a   Alfonso, P Garcia ^b   GirÓn, C Garcia ^c   Blanco, E ^d   BelOn J ^e   Garrido, P ^f   Jara, C ^g   Ruiz, A ^h   Vincent, J M ⁱ   Espinosa, E ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^d HOSPITAL INFANTA CRISTINA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g Hospital General   (Spain)

^h INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

5 Fluorouracil; Breast cancer; Gastric cancer; Head and neck cancer; Modulation; Non small cell lung cancer; Oral fluoropyrimidines; Tegafur; UFT

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IDARUBICIN; UFT;

ADULT; AGED; ALOPECIA; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COMBINATIONS; ETOPOSIDE; HEAD AND NECK NEOPLASMS; HUMANS; LEUCOVORIN; LUNG NEOPLASMS; MIDDLE AGED; STOMACH NEOPLASMS; TEGAFUR; URACIL;

EID: 0031060421     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227743     Document Type: Article

References (48)

1. Drewinko B, Yang LY: Cellular basis for the incfficacy of 5-FU in human colon carcinoma. Cancer Treat Rep 1985;69:1391-1398.
2. Fujii S, Ikenaka K, Fakushima M, Shirasaka T: Effect of Uracil and its derivatives on antitu-mor activity of clinical doses of l-(2-tetrahy-drofurvl)-5-fluorouracil. Gann 1978:69: 763-772.
3. Fujii S, Kitano S, Ikenaka K, Shirasaka T: Effect of coadministration of Uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tctrahydrofurvl)-5-fluorouracil and level of 5 fluorouracil in rodents. Gann 1979;70:209-214.
4. Taguchi T, Nakano Y, Fujii S, Shirasaka T: Determination of 5-fluorouracil levels in tumours. blood and other tissues. Cancer Che-mother 1978:5:1167-1172.
5. Cao S, Frank C, Shirasaka T, Rustum YM: 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin Cancer Res 1995:1:839-845.
6. Namatame K, Sasaki E, Ko Y, Shimada K, Takahashi H, Nakano H, Midorikawa T, Ma-kuuchi M, Kimura K, Kumada K: A doubleblind comparison of plasma Füra concentrations after oral administration of UFT and continuous intravenous infusion of FI. Jpn J Cancer Chemother 1993:20:2417-2419.
7. Palmeri S, Gebbia V, Russo A, Amata MG, Gebbia N, Rausa L: Oral Tegafur in the treatment of gastrointestinal tract cancer: A phase II study. Br J Cancer 1990:61:475-478.
8. Bjerkeset T, Fjosne HE: Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. Oncology 1986;43:212-215.
9. Murakami M, Ota K: Clinical results of UFT® therapy for malignant tumors under cooperative study (phase II study). Gan To Kagaku Ryoho 1980;7:2124-2129.
10. Estape J, Diaz-Rubio D, Guillem V, Montero JM, Garcia-Conde J, Martin M, Daniels M, Her-ranz C, Ordonez A: Phase 11 trial of UFT in several solid tumors (in Spanish. English abstract). Neoplasia 1986;3:57-60.
11. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vanden-bulcke JM. Missel JL, Schwarzenberg L: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986;4:685-696.
12. Doroshow JH, Leong L. Margolin K. Flanagan B, Goldberg D, Bertrand M, Akman S, Carr B, Odujinrin O, Newman E: Refractory metastatic breast cancer: Salvage therapy with fluorouracil and high-dosc continuous infusion leuco-vorin calcium. J Clin Oncol 1989:7:439-444.
13. Drcvfuss AI, Clark JR, Wright JE, Norris CM Jr., Busse PM, Lucarini JW, Fallon BG. Casey D, Andersen JW, Klein R: Continuous infusion of high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 1990:112: 167-172.
14. Lynch TJ, Kalish L, Fass F, Strauss G, Elias A, Skarin A, Shulman L. Sugerbakcr D, Frci E: Continuous-infusion cisplatin. 5-fluorouracil. and leucovorin for advanced non-small cell lung cancer. Cancer 1994:73:1171-1176.
15. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Mickish T, Nicolson V, Nash A, Sacks N, Ford M, Carter R, Hill A: A phase II study in advanced gastric cancer using epirubi-cin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994:9:805-812.
16. González-Barón M, Feliu J, Ordóñez A, Col-menarcjo A, Espinosa E, Zamora P, de la Gandara I, Jalón I: Phase I study of UFT’ plus leucovorin in advanced colorectal cancer: A double modulation proposal. Anticancer Res 1993;13:759-762.
17. González Barón Feliu J, de la Gándara I, Espinosa E, Colmenarejo A, Martinez B, Blanco E, Garcia Girón C, Juarez F. Garrido P, Ordóñez A, Zamora P: Efficacy of oral Tegafur modulation by Uracil (UFT®) and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 1995:31:2215-2219.
18. Findlay M, Cunningham D: Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993:19:29-44.
19. Pyrhónen S, Kuitunen T, Kouri M: A randomized phase III trial comparing fluorouracil. epi-doxorubicin and methotrexate (FAMtx) with best supportive care in non-rescctable gastric cancer (abstract). Ann Oncol 1992:3(suppl 5): 47.
20. Murad AM. Santiago FF. Pctroianu A, Rocha PR. Rodrigues MA, Raush M: Modified therapy with 5-fluorouracil. doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
21. Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ. Stahl M, Lenaz L, Meyer J, Siewert JR. Geerling H, Kóhnc-Wómper CH, Harstrick A, Schmoll HJ: New developments in the treatment of gastric carcinoma. Semin Oncol 1990:17:61-70.
22. Taal BG, Beijnen JH, Teller FGM, ten Bokkel Huinink WW, Dubbelman R, Boot H: Bioavailability of oral etoposide in gastric cancer. Eur J Cancer 1994:30:420-422.
23. Machara Y, Takcuchi H, Oshiro T, Takahashi I, Inutsuka S, Baba H, Hohnoe S, Sugimachi K: Effect of gastrectomy on the pharmacokinetics of Tegafur, Uracil, and 5-fluorouracil after oral administration of a 1:4 Tegafur and Uracil combination. Cancer Chemother Pharmacol 1994;33:445-449.
24. Plosker GL, Faulds D: Epirubiein, A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cancer chemotherapy. Drugs 1993:45:788-856.
25. Kris M, Gralla R. Wertheim H, Kclscn DP, O'Connell JP, Burke MT, Fiore JJ, Cibas IR, Hcelan RT: Trial of the combination of mitomycin. vindcsine and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 1986:70:1091-1096.
26. García Girón C, Ordóñez A, Jalón JI, Baron MG: Combination chemotherapy with ifos-famidc. mitomycin and cisplatin in advanced non-small cell lung cancer. Cancer Treat Rep 1987;71:851-853.
27. Heim W, Wampler GL, Lokich JJ, Brereton HD. Scialla SJ, La Luna F, Ahlgren JD, Nevin J, Fryer JG, Alt D: A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small cell lung cancer: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1991:9:2162-2166.
28. Schabel FM, Trader MW, Laster WR: Cis-diamminedichloroplatinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63:1459-1473.
29. Scanlon K, Newman E, Priest D: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl AcadSci USA 1986:83:8923-8925.
30. Tsai C, Hsiao S, Frey CM, Chang KT. Pcmg RP. Gazdar AF, Kramer BS: Combination cytotoxic effects of cis-diamminedichloroplatin-um (II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines. Cancer Res 1993:53:1079-1084.
31. Takechi T, Saito H, Oie S, Okabe H, Nakano K, Takeda S, Yamada Y. Unemi N, Tsukago-shi S: Synergistic interaction between UFT® and cisplatin in human solid tumor xenografts (abstract). Proc Am Assoc Cancer Res 1993:34: 1676.
32. Ichinose Y, Takanashi N, Yano T, Asoh H, Yokoyanta H, Tayama K, Hara N, Ohta M: A phase II trial of oral Tegafur and Uracil plus cisplatin in patients with inoperable non-small cell lung cancer. Cancer 1995:75:2677-2680.
33. Sugimoto Y, Ohe Y, Nishio K, Ohmori T, Morikaget, Fujiwara Y, Saijo N: Mechanisms of collateral sensitivity to fluorouracil of a cis-diammincdichloroplatinum II-resistant human non-small cell lung cancer cell line. Br J Cancer 1992:65:857-864.
34. Vokes EE, Lyss AP. Herndon JE, Cooper B, Perry MC, Vinciguerra V, Mason-Coughlin K. Green MR: Intravenous 6-thioguanine or cisplatin. fluorouracil, and leucovorin for advanced non-small cell lung cancer. A randomized phase II study of the Cancer and Leukemia Group B, Ann Oncol 1992:3:727-732.
35. Joseph UG, Sullivan DM. Hamm JT, Miller C, Sceger J, Blummenrcich MS, Woodcock TM: Phase II study of 5-fluorouracil (5FU). leucovorin (LV) and cisplatin (C) in unresectable nonsmall cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 1992; 11:1024.
36. Amrein PC, Weitzman SA: Treatment of squamous cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol 1985: 3:1632-1639.
37. Gonzalez-Bardn M, Vicente J, Tomas M, Martin G, Martorell V. Garcia-Giron C, Garrido P, Gavilan J, Zamora P: Phase II trial of cisplatin and Tegafur (ftorafur) as initial therapy in squamous cell carcinoma of the head and neck. Am J Clin Oncol 1990; 13:312-314.
38. Gonzalez-Baron M, Vicente J, Martin G, Artal A, Cebreiros I, Garcia-Giron C, Tomas M, Gavilan J, Martorell V. Zamora P: Phase II trial of carboplatin and Tegafur (ftorafur) as induction therapy in squamous cell carcinoma of the head and neck. Am J Clin Oncol 1990: 13:277-279.
39. Panagos G, Papadakou M, Xydakis E, Janninis J, Boukis H, Delaveres P: Intensive chemotherapy of advanced head and neck cancer with cisplatin, bleomycin, Tegafur and leucovorin. Ann Oncol 1992:3(suppl 5): 159.
40. Camps S, Soler JJ, Vicent JM, Godes M, Amorrortu J: Neoadjuvant treatment with cisplatin-um and UFT in epidermoid carcinoma of the head and neck (in Spanish, English abstract). Neoplasia 1991:8:87-91.
41. Valverde JJ, González JL, Dominguez S, Lopez PM, Alonso MC, Adrover E. Casado A, Rodriguez A, Lopez JA, Martin M: Neoadjuvant chemotherapy (CT) with cisplatin (CDDP) and 5-fluorouracil (5FU) vs cisplatin and ftorafur-uracil (UFT) in advanced squamous head and neck cancer (SHNC) (abstract). Proc Am Soc Clin Oncol 1993:12:909.
42. Tashiro H, Nomura Y, Ohsaki A: A double comparative study of Tegafur (FT) and UFT® (a combination of Tegafur and Uracil) in advanced breast cancer. Jpn J Clin Oncol 1994; 24:212-217.
43. Daniels M, Diaz-Rubio E, Guillem V, Montero JM, Garcia-Conde J, Estapc J, Martin M, Her-ranz C, Ordóñez A, Gazan A: Phase II trial of UFT® activity in pretreatcd breast cancer patients. Jpn J Clin Oncol 1993:23:363-365.
44. Kajanti MJ, Pyrhonen SO, Maiche AG: Oral Tegafur in the treatment of metastatic breast cancer: A phase II study. Eur J Cancer 1993,29: 863-866.
45. Loprinzi CL: 5-Fluorouracil with leucovorin in breast cancer. Cancer 1989:63:1045-1047.
46. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989:7:890-899.
47. Sole LA, Albanell J, Bellmunt J, Ribas A, Gallego OS, Carulla J: Phase II trial of an all-oral regimen of Tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer 1995:75:831-835.
48. Soli LA, Ribas A, Bellmunt J, Gallardo E, Vidal R, Vera R, Carulla J, Albanell J: High response rate with a CMF-bascd regimen in advanced and metastatic breast cancer (MBC). Preliminary results (abstract). Proc Am Soc Clin Oncol 1996:15:115.